Related references
Note: Only part of the references are listed.Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
Han Fu et al.
NATURE COMMUNICATIONS (2021)
The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China
Chathika K. Weerasuriya et al.
BMC MEDICINE (2021)
Regional changes in tuberculosis disease burden among adolescents in South Africa (2005-2015)
Erick Wekesa Bunyasi et al.
PLOS ONE (2020)
Potential impact of tuberculosis vaccines in China, South Africa, and India
Rebecca C. Harris et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa
Fiammetta M. Bozzani et al.
VALUE IN HEALTH (2020)
New tuberculosis vaccines: advances in clinical development and modelling
C. K. Weerasuriya et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Evaluating vaccination strategies for tuberculosis in endemic and non-endemic settings
Marissa Renardy et al.
JOURNAL OF THEORETICAL BIOLOGY (2019)
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
D. R. Tait et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey
Nazir Ahmed Ismail et al.
LANCET INFECTIOUS DISEASES (2018)
Prevention of M-tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
E. Nemes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review
David Cameron et al.
GLOBAL HEALTH ACTION (2018)
Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data
Jessica Ochalek et al.
BMJ GLOBAL HEALTH (2018)
Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case
Gesine Meyer-Rath et al.
PLOS ONE (2017)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials
Punam Mangtani et al.
CLINICAL INFECTIOUS DISEASES (2014)
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries
Gwenan M. Knight et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study
Chia-Lin Tseng et al.
BMC PUBLIC HEALTH (2011)
Share Paper
